arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ENANTA PHARMACEUTICALS INC

ENTA
$10.05 ▼ -0.59 (-5.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
60 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

ENANTA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $292.4M
Dividend Yield —
Revenue Growth -21.6% ↘
Op. Margin -120.0% ↘
ROIC -17.1% ↘
FCF / Share $-0.34 ↘
Trailing P/E —
Price / Book 2.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

60-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.36M
↓ -21.6% —
Net Income Profit after all expenses
$-11.94M
↑ +46.4% —
Operating Margin Operating profit as % of sales
-120.0%
↓ -73.8% 1th
FCF / Share Free cash flow per share
$-0.34
↓ -38.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
3
Returns ↓
6
Financial Health
31
Cash Quality ↓
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 16 years · 60 quarters